Clinical Care
Committed to improving patient outcomes
Building on more than 50 years of trailblazing liver treatment, our team of hepatologists and transplant surgeons are dedicated to patient-centered care. As the Stravitz-Sanyal Institute expands, more revolutionary treatment options will become available for patients with liver diseases.
Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis or NASH, is a chronic form of fatty liver disease that is often the precursor to advanced liver disease and a leading cause for liver transplantation. Unrelated to alcohol abuse but closely linked to obesity and Type 2 diabetes, MASH generates a buildup of fat in the liver that damages cells and causes inflammation. For many patients, MASH can cause scarring, or fibrosis, which prevents the liver from functioning properly and can lead to cirrhosis. In severe cases, the condition can lead to liver cancer, liver failure or death.
Our clinician-researchers are actively investigating new treatment methods for MASH. In 2019, a Phase III clinical trial was the first to demonstrate the safety and effectiveness of an oral medication to treat MASH, and in 2024, the U.S. Food and Drug Administration approved the first drug to treat the liver disease. Our director, Arun Sanyal, M.D., and others among our faculty continue to publish findings that are closing the gaps in knowledge and awareness of MASH and metabolic dysfunction-associated steatotic liver disease. We lead studies of new potential therapies that may someday treat MASH and liver fibrosis.
We are expanding our efforts to understand other aspects of liver disease, including liver cancer, alcohol-related liver disease, hepatitis, biliary atresia, factors that affect liver transplants, and primary sclerosing cholangitis. As we improve our understanding of these diseases, there is a better chance of developing viable treatment options for patients.
Advanced Liver Disease Program
Our dedicated physicians and nurses treat patients with more than 100 conditions and diseases known to affect the liver, including viral hepatitis, metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma.
Hume-Lee Transplant Center
Providing compassionate care with survival rates at or above the national average, Hume-Lee performs liver transplants for the treatment of diseases such as fatty liver disease, acute liver failure and primary biliary cirrhosis.